8-K: Candel Therapeutics Reports Promising Survival Data for CAN-2409 in Lung Cancer Trial

Candel Therapeutics announced positive topline data from its Phase 2 trial of CAN-2409, showing a significant increase in overall survival for lung cancer patients who did not respond to prior immunotherapy.

Summary

• Candel Therapeutics reported topline data from a Phase 2 clinical trial of CAN-2409 in patients with advanced non-small cell lung cancer (NSCLC) who had not responded to immune checkpoint inhibitor (ICI) therapy.
• The trial showed a median overall survival (mOS) of 20.6 months in patients treated with CAN-2409 plus valacyclovir, compared to a published mOS of 11.6 months for standard chemotherapy in a similar patient group.
• Across all 46 patients in the trial, the mOS was 22.0 months.
• The treatment also demonstrated a systemic immune response, with increased circulating cytotoxic and memory T cells, and a beneficial effect on both injected and uninjected tumors.
• The safety profile of CAN-2409 remained favorable, with no dose-limiting toxicities or grade 4 or higher treatment-related adverse events.

Sentiment

Score: 8

Explanation: The document presents very positive clinical trial results with a significant improvement in overall survival and a favorable safety profile. The management commentary is also optimistic, and the company has received FDA Fast Track Designation for CAN-2409. However, it is still early stage data and there are risks associated with clinical trials and regulatory approvals.

Positives

• The median overall survival of 20.6 months in patients with progressive disease is a significant improvement compared to the 11.6 months seen with standard chemotherapy.
• The treatment showed a systemic immune response, indicating that it is not just working locally at the tumor site.
• The favorable safety and tolerability profile suggests that CAN-2409 could be a viable treatment option for patients with limited alternatives.
• The abscopal response, where both injected and uninjected tumors are affected, is a positive sign of the treatment's effectiveness.

Negatives

• The trial was an open-label phase 2 study, which may introduce bias compared to a randomized controlled trial.
• The data is based on a specific cut-off date (April 1, 2024), and further follow-up may reveal different results.
• The study population was limited to patients who had not responded to prior immunotherapy, which may not be representative of all NSCLC patients.

Risks

• The results are from a Phase 2 trial, and further Phase 3 trials are needed to confirm the efficacy and safety of CAN-2409.
• The company's ability to continue as a going concern is a risk factor mentioned in the forward-looking statements.
• Regulatory approval is not guaranteed, and the company may face challenges in obtaining and maintaining it.
• The company's intellectual property may be challenged, which could impact its ability to commercialize CAN-2409.

Future Outlook

The company plans to continue the development of CAN-2409 in NSCLC and other solid tumors, with the potential to convert progressive cancer into stable disease associated with survival benefit. They are also evaluating CAN-2409 in other cancers such as pancreatic and prostate cancer.

Management Comments

• Paul Peter Tak, MD, PhD, FMedSci, President and Chief Executive Officer of Candel, stated that the improved overall survival is what matters to patients and regulators.
• He also noted that the results, along with data in pancreatic cancer, support the notion that CAN-2409 treatment may convert progressive cancer into stable disease associated with survival benefit.
• Charu Aggarwal, MD, MPH, FASCO, mentioned that the data suggests CAN-2409 can reactivate exhausted immune systems, including those with low PD-(L)1 expression.

Industry Context

The announcement is significant in the context of the limited treatment options available for advanced NSCLC patients who do not respond to initial immunotherapy. The results suggest that CAN-2409 could address a significant unmet need in this patient population. The company is also exploring the use of CAN-2409 in other solid tumors, which could expand its market potential.

Comparison to Industry Standards

• The median overall survival of 20.6 months with CAN-2409 is a notable improvement compared to the 11.6 months reported for docetaxel-based chemotherapy in a similar patient population, as published in a 2022 study by Reckamp KL, et al.
• This suggests that CAN-2409 may offer a more effective treatment option for patients who have progressed on immune checkpoint inhibitors.
• While direct comparisons to other experimental therapies are not provided in the document, the data indicates a potential for CAN-2409 to become a competitive treatment in the NSCLC space.
• The abscopal response observed in over 60% of patients is also a positive indicator, as it suggests a systemic immune response that could be more effective than treatments that only target the primary tumor.

Stakeholder Impact

• Shareholders may view the positive clinical trial results favorably, potentially leading to an increase in the company's stock price.
• Patients with advanced NSCLC may benefit from a new treatment option that has shown promising results.
• Employees of Candel may be motivated by the positive results and the potential for the company to bring a new therapy to market.
• The medical community may be interested in the data and the potential of CAN-2409 to address an unmet need.

Next Steps

• The company will present the data at the 2024 ASCO Annual Meeting on June 3, 2024.
• Candel will continue the development of CAN-2409 in NSCLC and other solid tumors.
• The company is also evaluating CAN-2409 in ongoing clinical trials for pancreatic and prostate cancer.

Key Dates

Keywords

CAN-2409, Non-Small Cell Lung Cancer, NSCLC, Immunotherapy, Immune Checkpoint Inhibitor, ICI, Overall Survival, Abscopal Response, T Cells, Clinical Trial